Trial Profile
An Open-Label, Phase 1 Study of the Safety and Immunogenicity of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects With Metastatic Castration-resistant Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs Opolimogene-capmilisbac (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Aduro BioTech; Janssen Biotech
- 04 Jun 2019 Status changed to discontinued, according to the results presented at the 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 04 Jun 2019 Safety and efficacy results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 15 Jun 2018 Planned End Date changed from 15 Jun 2018 to 10 Jul 2018.